Compare F & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | F | NTRA |
|---|---|---|
| Founded | 1903 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.2B | 47.4B |
| IPO Year | 2008 | 2015 |
| Metric | F | NTRA |
|---|---|---|
| Price | $13.36 | $348.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $13.41 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 36.3M | 1.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $184,992,000,000.00 | $210,939,000.00 |
| Revenue This Year | N/A | $18.08 |
| Revenue Next Year | $1.23 | $19.65 |
| P/E Ratio | $21.44 | ★ N/A |
| Revenue Growth | ★ 5.00 | N/A |
| 52 Week Low | $11.11 | $157.43 |
| 52 Week High | $17.78 | $343.18 |
| Indicator | F | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 70.58 |
| Support Level | $13.26 | $187.64 |
| Resistance Level | $14.35 | N/A |
| Average True Range (ATR) | 0.41 | 10.20 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 23.83 | 97.21 |
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has over 13% market share in the United States, about 10% share in the UK, and just over 1% share in China including Taiwan and unconsolidated affiliates. Sales in the US made up about 65% of 2025 total company revenue. Ford has about 169,000 employees, including about 56,300 UAW employees, and is based in Dearborn, Michigan.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.